Skip to main content
ES
v1.2
Log in
M

Marksans Pharma

MARKSANS PHARMANSE
₹317+0.00 (+0.00%)
Market Cap
₹14,077Cr.
P/E Ratio
27.2
P/B Ratio
4.75
EPS (TTM)
₹11.65
Div Yield
0.28%
ROCE
18.8%
ROE
15.2%
52W Low: ₹15552W High: ₹351

At a glance

  • Sales have grown 17.0% a year over three years.
  • Debt is 0.11× its shareholders’ equity.

From reported financials and exchange prices. Descriptive only, not advice.

Marksans_Pharma — Price
Interval
||
Style
Failed: 503

Scorecard

Market: risk-off · breadth 37
7/8Minerviniuptrend checks met
90RS Rankvs all stocks, 1–99
bullRSI Regimemomentum range
16Trend (ADX)trend strength
1/4CAN SLIMprice & volume checks
upSupertrendprice vs trailing line
upVolume Flowbuying vs selling volume

Factual technical classifications from price/volume data — research signals, not investment advice. Hover or tap any badge for what it means.

Evenstocks Score

Middle third
5.8/ 10Overall
5/ 10Valuation
7/ 10Quality
4/ 10Fundamental
7/ 10Growth

Investment Checklist

Quick assessment based on key parameters
Performance
N/ATrailing return unavailable
Valuation
P/E 27.2P/E: 27.2 | P/B: 4.75
Growth
GrowingSales CAGR — 3Y: 17% · 1Y: 20%
Profitability
ModerateROCE: 18.8% | ROE: 15.2%

Key Metrics

Valuation
PEG Ratio 1.70
Price / Sales 4.44x
Price / FCF 42.8x
Book Value ₹66.7
Margins & returns
Operating Margin 22%
Net Margin 16.4%
Return on Assets 13.5%

Frequently Asked Questions

MarketsPortfolioChart